Information sur le cancer / Types de cancer / Thymus / Recherche

Besse B, Garassino MC, Rajan A et al. A phase II study of milciclib (PHA-848125AC) in patients with thymic carcinoma. (2014). 2014 ASCO Annual Meeting. Alexandria, VA: American Society of Clinical Oncology. Abstract 7526. Extrait de: http://meetinglibrary.asco.org/content/131226-144.

Chao YK, Liu YH, Hsieh MJ et al. Long-term outcomes after thoracoscopic resection of stage I and II thymoma: a propensity-matched study. (2015, April). Annals of Surgical Oncology. 22(4):1371-1376.

Fan C, Feng Q, Chen Y et al. Postoperative radiotherapy for completely resected Masaoka stage III thymoma: a retrospective study of 65 cases from a single institution. (2013, August 13). Radiation Oncology. 8:199. Extrait de: http://ro-journal.biomedcentral.com/articles/10.1186/1748-717X-8-199.

Friedant AJ, Handorf EA, Su S, Scott WJ. Minimally invasive versus open thymectomy for thymic malignancies: systematic review and meta-analysis. (2016, January). Journal of Thoracic Oncology. 11(1):30-38.

Gubens MA, Burns M, Perkins SM et al. A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies. (2015, July). Lung Cancer. 89(1):57-60.

Hirai F, Yamanaka T, Taguchi K et al. A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L. (2015, February). Annals of Oncology. 26(2):363-368. Extrait de: http://annonc.oxfordjournals.org/content/26/2/363.long.

Korst RJ, Bezjak A, Blackmon S et al. Neoadjuvant chemoradiotherapy for locally advanced thymic tumors: a phase II, multi-institutional clinical trial. (2014, January). Journal of Thoracic and Cardiovascular Surgery. 147(1):36-46.e1. Extrait de: http://www.jtcvsonline.org/article/S0022-5223(13)01043-X/fulltext.

Lopez-Chavez A, Thomas A, Rajan A et al. Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. (2015, March 20). Journal of Clinical Oncology. 33(9):1000-1007. Extrait de: http://jco.ascopubs.org/content/33/9/1000.long.

Luo Y, Li JL, Yang L, Zhang W. Chemotherapy with gemcitabine plus cisplatin in patients with advanced thymic squamous cell carcinoma: evaluation of efficacy and toxicity. (2016, March). Thoracic Cancer. 7(2):167-172. Extrait de: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4773311/.

Palmieri G, Buonerba C, Ottaviano M et al. Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a Phase II trial. (2014, November). Future Oncology. 10(14):2141-2147.

Parikh RR, Rhome R, Hug E et al. Adjuvant proton beam therapy in the management of thymoma: a dosimetric comparison and acute toxicities. (2016, June 8). Clinical Lung Cancer. doi: 10.1016/j.cllc.2016.05.019.

Park S, Ahn MJ, Ahn JS et al. A prospective phase II trial of induction chemotherapy with docetaxel/cisplatin for Masaoka stage III/IV thymic epithelial tumors. (2013, July). Journal of Thoracic Oncology. 8(7):959-966. Extrait de: http://www.jto.org/article/S1556-0864(15)32881-1/fulltext.

Rajan A, Carter CA, Berman A et al. Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. (2014, February). Lancet Oncology. 15(2):191-200. Extrait de: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3954701/.

Ried M, Potzger T, Braune N et al. Cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion for malignant pleural tumours: perioperative management and clinical experience. (2013, April). European Journal of Cardio-Thoracic Surgery. 43(4):801-807. Extrait de: http://ejcts.oxfordjournals.org/content/43/4/801.long.

Thomas A, Rajan A, Berman A et al. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. (2015, February). Lancet Oncology. 16(2):177-186. Extrait de: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4401497/.

Thomas A, Rajan A, Szabo E et al. A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study. (2014, November 1). Clinical Cancer Research. 20(21):5392-5402. Extrait de: http://clincancerres.aacrjournals.org/content/20/21/5392.long.

US National Institutes of Health. ClinicalTrials.gov.

Vogel J, Berman AT, Lin L et al. Prospective study of proton beam radiation therapy for adjuvant and definitive treatment of thymoma and thymic carcinoma: Early response and toxicity assessment. (2016, March). Radiotherapy and Oncology. 118(3):504-509.

Wang H, Gu Z, Ding J et al. Perioperative outcomes and long-term survival in clinically early-stage thymic malignancies: video-assisted thoracoscopic thymectomy versus open approaches. (2016, April). Journal of Thoracic Disease. 8(4):673-679. Extrait de: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824723/.

Yu L, Jing Y, Ma S, Li F, Zhang YF. Cytoreductive surgery combined with hyperthermic intrapleural chemotherapy to treat thymoma or thymic carcinoma with pleural dissemination. (2013, May 10). OncoTargets and Therapy. 6:517-521. Extrait de: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3656918/.